SCI Abstract

search
+
Chapter Three - Insight gained from using animal models to study pain in Parkinson’s disease
Chapter Three - Insight gained from using animal models to study pain in Parkinson’s disease
Pain is one of the key non-motor symptoms experienced by a large proportion of people living with Parkinson’s disease (PD)...
Chapter Four - Investigating affective neuropsychiatric symptoms in rodent models of Parkinson’s disease
Chapter Four - Investigating affective neuropsychiatric symptoms in rodent models of Parkinson’s disease
Affective neuropsychiatric disorders such as depression, anxiety and apathy are among the most frequent non-motor symptoms...
Chapter Five - Macro and micro-sleep dysfunctions as translational biomarkers for Parkinson’s disease
Chapter Five - Macro and micro-sleep dysfunctions as translational biomarkers for Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disease, afflicting about 1% of people over 65 years ...
Chapter Six - Review: Lower urinary tract dysfunction in animal models of Parkinson’s disease (PD): Translational aspects for the treatment of PD patients with overactive bladder
Chapter Six - Review: Lower urinary tract dysfunction in animal models of Parkinson’s disease (PD): Translational aspects for the treatment of PD patients with overactive bladder
Parkinson’s disease (PD) is a neurodegenerative disorder caused by the loss of dopaminergic neurons in the substantia nigr...
Chapter Seven - Executive dysfunction and cognitive decline, a non-motor symptom of Parkinson’s disease captured in animal models
Chapter Seven - Executive dysfunction and cognitive decline, a non-motor symptom of Parkinson’s disease captured in animal models
Parkinson’s disease (PD) is a complex and progressive neurodegenerative disorder primarily characterised by motor symptoms...
Chapter One - AUD in perspective
Chapter One - AUD in perspective
Alcohol is a major cause of pre-mature death and individual suffering worldwide, and the importance of diagnosing and trea...
Chapter Two - Alcohol and the dopamine system
Chapter Two - Alcohol and the dopamine system
The mesolimbic dopamine pathway plays a major role in drug reinforcement and is likely involved also in the development of...
Chapter Three - GABAergic mechanisms in alcohol dependence
Chapter Three - GABAergic mechanisms in alcohol dependence
In 2014, it was estimated that brain diseases were responsible for 35% of Europe’s disease burden, with addictions having ...
Chapter Four - Current treatments of alcohol use disorder
Chapter Four - Current treatments of alcohol use disorder
Emerging treatments for alcohol dependence reveal an intricate interplay of neurobiological, psychological, and circumstan...
Chapter Five - Repurposing drugs for treatment of alcohol use disorder
Chapter Five - Repurposing drugs for treatment of alcohol use disorder
Repurposing drugs for the treatment of alcohol dependence involves the use of drugs that were initially developed for othe...
Chapter Six - Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy
Chapter Six - Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy
Julien Guiraud is employed by Vergio, Clichy, France and was employed by D&A Pharma until March 2022.Wim van den Brink...
Chapter Seven - Reducing the harms of alcohol: nutritional interventions and functional alcohol alternatives
Chapter Seven - Reducing the harms of alcohol: nutritional interventions and functional alcohol alternatives
While GABA is the main inhibitory transmitter in the brain, the last three decades have seen an increased appreciation of ...
Chapter Eight - Designing and testing treatments for alcohol use disorder
Chapter Eight - Designing and testing treatments for alcohol use disorder
Developing new treatments for AUD or personalizing existing treatments for AUD requires extensive consideration of researc...
Chapter Nine - Phosphatidylethanol (B-PEth) and other direct and indirect biomarkers of alcohol consumption
Chapter Nine - Phosphatidylethanol (B-PEth) and other direct and indirect biomarkers of alcohol consumption
Correct information of the actual alcohol intake is essential to assess the correlation with alcohol risk level consumptio...
Setting the clinical context to non-motor symptoms reflected by Park-pain, Park-sleep, and Park-autonomic subtypes of Parkinson’s disease
Setting the clinical context to non-motor symptoms reflected by Park-pain, Park-sleep, and Park-autonomic subtypes of Parkinson’s disease
Dr James Parkinson, in 1817, first described a condition based on observation of motor features ranging from shaking to po...
Macro and micro-sleep dysfunctions as translational biomarkers for Parkinson’s disease
Macro and micro-sleep dysfunctions as translational biomarkers for Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disease, afflicting about 1% of people over 65 years ...
Half Title Page
Half Title Page
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of c...
Series Page
Series Page
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of c...
Chapter One - The dopamine hypothesis of autism spectrum disorder: A comprehensive analysis of the evidence
Chapter One - The dopamine hypothesis of autism spectrum disorder: A comprehensive analysis of the evidence
Autism spectrum disorder (ASD) remains a public health concern, as recent prevalence estimates of ASD are as high as 1 in ...
Chapter Two - A review of the use of psychotropic medication to address challenging behaviour in neurodevelopmental disorders
Chapter Two - A review of the use of psychotropic medication to address challenging behaviour in neurodevelopmental disorders
Engagement in challenging behaviour (e.g., aggression, self-injury) is reported to occur in neurodevelopmental disorders s...
Chapter Three - Involvement of brain metabolism in neurodevelopmental disorders
Chapter Three - Involvement of brain metabolism in neurodevelopmental disorders
Metabolism represents a series of biochemical pathways that provide cells with solutions to utilize and produce energy, to...
Chapter Four - Cholesterol alterations in fragile X syndrome, autism spectrum disorders and other neurodevelopmental disorders
Chapter Four - Cholesterol alterations in fragile X syndrome, autism spectrum disorders and other neurodevelopmental disorders
Autism spectrum disorder (ASD) refers to a group of neurodevelopmental disorders that manifests during early childhood. AS...
Chapter Five - Toward an understanding of the role of the exposome on fragile X phenotypes
Chapter Five - Toward an understanding of the role of the exposome on fragile X phenotypes
Fragile X syndrome (FXS) is the leading known monogenetic cause of autism with an estimated 21–50% of FXS individuals meet...
Chapter Six - How dendritic spines shape is determined by MMP-9 activity in FXS
Chapter Six - How dendritic spines shape is determined by MMP-9 activity in FXS
Fragile X syndrome (FXS) is the leading inherited intellectual disability and the most prevalent single-gene cause of auti...
Chapter Seven - Glial-mediated dysregulation of neurodevelopment in Fragile X Syndrome
Chapter Seven - Glial-mediated dysregulation of neurodevelopment in Fragile X Syndrome
Since the discovery of the genetic mutation in Fragile X Syndrome (FXS) and the resulting absence of the fragile X messeng...
How dendritic spines shape is determined by MMP-9 activity in FXS
How dendritic spines shape is determined by MMP-9 activity in FXS
Fragile X syndrome (FXS) is the leading inherited intellectual disability and the most prevalent single-gene cause of auti...
Chapter One - Spinal cord injury induced exacerbation of Alzheimer's disease like pathophysiology is reduced by topical application of nanowired cerebrolysin with monoclonal antibodies to amyloid beta peptide, p-tau and tumor necrosis factor alpha
Chapter One - Spinal cord injury induced exacerbation of Alzheimer's disease like pathophysiology is reduced by topical application of nanowired cerebrolysin with monoclonal antibodies to amyloid beta peptide, p-tau and tumor necrosis factor alpha
Spinal cord injury across the World is one of the prominent causes of disability in military as well as the civilians for ...
Chapter Two - Nanodelivery of histamine H3 receptor inverse agonist BF-2649 with H3 receptor antagonist and H4 receptor agonist clobenpropit induced neuroprotection is potentiated by antioxidant compound H-290/51 in spinal cord injury
Chapter Two - Nanodelivery of histamine H3 receptor inverse agonist BF-2649 with H3 receptor antagonist and H4 receptor agonist clobenpropit induced neuroprotection is potentiated by antioxidant compound H-290/51 in spinal cord injury
Spinal cord injury cases worldwide are about 50–80 per million population largely affecting males during traffic accidents...
Chapter Three - Neuromodulation and quality of life for patient with spasticity after spinal cord injury
Chapter Three - Neuromodulation and quality of life for patient with spasticity after spinal cord injury
Advances of the modern medicine require reconceptualization of the existing approaches to therapy of neurological diseases...
Chapter Four - Efficacy of invasive and non-invasive methods for the treatment of Parkinson’s disease: Nanodelivery and enriched environment
Chapter Four - Efficacy of invasive and non-invasive methods for the treatment of Parkinson’s disease: Nanodelivery and enriched environment
Parkinson’s disease (PD) is the most common neurodegenerative disorder after Alzheimer’s disease, affecting 1–2% of the po...
Load More
format_indent_increase